FO
AKBA icon

FT Options’s Akebia Therapeutics AKBA Stock Holding History

FT Options’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.45M Buy
190,400
+39,100
+26% +$601K 2.19% 10
2017
Q2 		$633K Buy
151,300
+97,600
+182% +$1.24M 1.09% 25
2017
Q1 		$83K Sell
53,700
-81,900
-60% -$800K 0.11% 127
2016
Q4 		$94K Buy
135,600
+100,600
+287% +$866K 0.11% 105
2016
Q3 		$8K Hold
35,000
– – 0.01% 311
2016
Q2 		$13K Buy
35,000
+2,700
+8% +$23.6K 0.01% 277
2016
Q1 		$57K Buy
32,300
+24,800
+331% +$201K 0.06% 154
2015
Q4 		$8K Buy
+7,500
New +$76.5K 0.01% 185

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FT Options's AKBA Position: Q3 2017 in Review

FT Options sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 30 shares — an estimated $461 sold.

FT Options first reported a position in AKBA in Q4 2015 and held it in 7 quarters. The position peaked at $3.52M in Q4 2016. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

  • FT Options reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • FT Options sold 30 Akebia Therapeutics shares in Q3 2017, an estimated $461.
  • FT Options first reported a position in Akebia Therapeutics in Q4 2015 and held it in 7 quarters.
  • FT Options's Akebia Therapeutics position peaked at $3.52M in Q4 2016.
  • 119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.